We use some essential cookies to make this website work.
We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You have accepted additional cookies. You can change your cookie settings at any time.
You have rejected additional cookies. You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
Guidance, key documents, and CMA decisions on the review of PPU arrangements under the Private Healthcare Market Investigation Order 2014.
Collection of information and guidance for patients and for healthcare professionals on the reproductive risks of valproate and new safety measures introduced to reduce these risks.
Accord-UK Ltd is recalling a specific batch of Co-Codamol 8/500mg Effervescent Tablets (Key Pharmaceuticals Livery) as a precautionary measure due to the internal tablet blister strips being printed with an incorrect expiry date.
The government’s plans for the NHS and social care to deliver for patients, this winter and next.
Past and current clinical trials into therapeutic and antiviral treatments for COVID-19, how to take part, and which treatments have proven to be effective.
A new pathway supporting innovative approaches to the safe, timely and efficient development of medicines to improve patient access.
How to package medicines for sale and what information you must provide to consumers and healthcare professionals.
This document sets out what criteria are considered when designating a restricted patient ‘high profile’.
Information about the risks of taking valproate medicines during pregnancy.
Support for providers and commissioners to make evidence-based appraisals of how the benefits compare with the costs of various approaches to move care closer to home.
The Medicines and Healthcare products Regulatory Agency (MHRA) has today (11 March 2024) approved the medicine quizartinib (Vanflyta) to be used alongside chemotherapy as first line treatment for adults who have acute myeloid leukaemia (AML).
The Secretary of State for Health and Social Care makes a statement on action the government is taking to improve patient choice to help cut NHS waiting times.
Patients will be given more choice and greater control over their own care, including through the NHS App.
Recommendations to improve patient safety in the NHS in England.
Don’t include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. We’ll send you a link to a feedback form. It will take only 2 minutes to fill in. Don’t worry we won’t send you spam or share your email address with anyone.